Atara receives action date for tabcel
Thousand Oaks-based Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, received acceptance by the U.S. Food and Drug Administration of the Biologics License Application for tabelecleucel, Atara’s lead product, on Oct. 14. With the notice, the FDA also set a target action date for the drug on March 31. Tabelecleucel, sold under the brand Read More →

Moorpark College, CSUCI partner on new bachelor program in cybersecurity
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Rona inks deal worth up to $1.16B to license obesity drug
Rona Therapeutics, a world-leading RNAi therapeutics company dedicated to addressing cardiometabolic, obesity and degenerative diseases with a next-generation RNA technology platform, announced it has entered into an exclusive worldwide licensing agreement worth up to $1.16 billion with Roche for its investigational obesity drug candidate. Rona is based in Shanghai, China, but maintains a U.S. headquarters Read More →

Emergency prep 2026: How to remain protected against El Niño
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Report highlights Central Coast as aerospace hub
A new report makes the case that with 7,000 companies employing some 80,000 workers, the region should be recognized as major hub for aerospace and autonomous systems. Called “The Central Coast: Built to Prove What’s Next,” the report catalogues a number of familiar assets, and some new initiatives. The report was released by a group Read More →








